🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesGLP-1 and atrial fibrillation risk — November 2025 Page 3

GLP-1 and atrial fibrillation risk — November 2025

NurseLeah_Nash Mon, Oct 20, 2025 at 7:42 AM 39 replies 2,030 viewsPage 3 of 8
NurseKim_ATL
Senior Member
1,678
7,234
Feb 2024
Atlanta, GA
Oct 21, 2025 at 9:28 PM#11
Dr.RenalNash said:
Cardiac biomarkers and cardiovascular risk: my cardiologist ordered advanced cardiac labs given my family history.

Anti-inflammatory mechanisms of GLP-1 agonists and cardiovascular risk: beyond weight loss, GLP-1R activation directly suppresses NF-κB signaling, reduces NLRP3 inflammasome activation, and decreases monocyte/macrophage adhesion to endothelium[1].

Clinical correlates: hsCRP reduction of 30-60% (consistently seen across trials), reduced carotid intima-media thickness, and decreased coronary plaque inflammation on PET imaging.

These anti-inflammatory effects likely contribute to the cardiovascular benefit seen in SELECT — and may explain benefits beyond what weight loss alone would predict.

References:
[1] Hogan AE, et al. Diabetologia. 2014;57(4):781-784.
1 1denise_HTX
Reply Quote Save Share Report
mike_mealprep
Member
412
1,890
Jul 2024
Chicago, IL
Oct 22, 2025 at 1:29 PM#12
emma_london said:
Metabolic syndrome resolution on cardiovascular risk: I went from meeting 5 of 5 diagnostic criteria to meeting ZERO after 13 months of treatment.

This is exactly what I could not find anywhere else. Adding it to my notes with a link back to this thread.

Last edited: Oct 22, 2025 at 7:29 PM
50 0newstart_MO, mia_MS2, LeilaHI and 47 others
Reply Quote Save Share Report
JenMemphis
Member
267
1,234
Jan 2025
Memphis, TN
Oct 23, 2025 at 5:29 AM#13
Dr.RenalNash said:
Cardiac biomarkers and cardiovascular risk: my cardiologist ordered advanced cardiac labs given my family history.

Vitamin deficiency cascade with cardiovascular risk: after 6+ months of reduced food intake, I developed a subtle but important pattern: low B12 → elevated homocysteine → increased cardiovascular risk marker.

The connection: B12 is a cofactor for homocysteine metabolism. Without adequate B12, homocysteine accumulates. This is ironic — taking a CV-protective medication while developing a CV risk factor from reduced nutrition.

Solution: comprehensive vitamin supplementation and regular lab monitoring. Don't let the medication's benefits be undermined by nutritional deficiencies.

49 24NurseAsh_DET, BenResearch_OR, MikeKY_noInsulin and 46 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
DoseLogDan
Member
201
567
Feb 2025
Montana
Oct 23, 2025 at 9:29 PM#14
NurseLeah_Nash said:
My reason for being on this is cardiovascular rather than cosmetic, which puts me in a small minority in most of these threads.

Continuous metabolic monitoring dashboard for cardiovascular risk — I track everything in a spreadsheet and here's the month-over-month trend for my key markers:

Weight: consistent downtrend, -1.6 lbs/week average
Fasting glucose (finger stick): stable at 85 mg/dL
Blood pressure (home): 116/75 average
Resting heart rate: 65 bpm (down from 81)
Waist circumference: down 15 inches total

The resting heart rate improvement correlates with cardiovascular fitness gains. Everything is moving in the right direction.

48 23sophie_paris, mel_PDX, Dr.AddMedPHL and 45 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Oct 24, 2025 at 1:29 PM#15

Moderator note: a post naming a supplier has been edited. Discuss suppliers in the review sections, not here. Report rather than reply if it drifts again.

47 22PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 44 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register